LENZ shares slide on weak first commercial quarter results
VIZZ eye treatment generates $1.6M in debut quarter, missing analyst expectations
LENZ Therapeutics shares tumbled Tuesday after the biotechnology company reported its first commercial quarter following the October launch of VIZZ, its eye drop treatment for age-related vision loss. The results fell well short of Wall Street expectations, raising questions about the pace of adoption for what management has described as a 'best-in-class' therapy.
The company recorded net product revenue of $1.6 million for the fourth quarter of 2025, significantly below the $4.6 million that analysts had anticipated. The per-share loss of $1.16 represented a 68 percent miss against the consensus estimate of a 69-cent loss, according to the company's earnings announcement. The stock, which closed at $11 on Monday, has lost 58 percent of its value compared with its 200-day moving average of $27.74.
The commercial performance of VIZZ (aceclidine ophthalmic solution) represents a critical test for LENZ, which received FDA approval for the presbyopia treatment on July 31, 2025. VIZZ became the first and only aceclidine-based eye drop approved in the United States for the condition, which affects approximately 128 million Americans and causes difficulty focusing on nearby objects as people age.
Management sought to emphasize positive indicators from the early launch phase. During the fourth quarter, more than 20,000 prescriptions were filled, with over 6,500 unique prescribers writing for the product. The company projects that paid prescriptions will exceed 45,000 from launch through the first quarter of 2026, with prescriber numbers growing to more than 10,000. More than 55 percent of eye care professionals who prescribed VIZZ have done so multiple times, suggesting some repeat business, according to company data.
'We are encouraged by the early performance of VIZZ and are seeing broad prescriber uptake across the country with encouraging early refill trends that reinforce its best-in-class profile,' said Eef Schimmelpennink, president and chief executive officer of LENZ Therapeutics.
However, the costs of building a commercial presence have mounted. Selling, general and administrative expenses surged to $39.6 million in the fourth quarter, up from $9.4 million in the same period of 2024. For the full year, SG&A reached $91.1 million, more than triple the prior year's $28.8 million, reflecting the expansion of a sales force to 88 territories and preparations for marketing campaigns. Research and development spending, by contrast, declined to zero in the fourth quarter as clinical development for VIZZ concluded.
The company is pressing forward with expansion plans, announcing it will grow its sales organization from 88 to 117 territories, with full deployment expected by the second quarter of 2026. A direct-to-consumer campaign featuring actress Sarah Jessica Parker launched in January across digital platforms, with network television advertising planned for select markets in early April 2026. Website traffic to VIZZ.com increased by as much as tenfold following national media activations, the company said.
LENZ ended the year with $292.3 million in cash, cash equivalents and marketable securities. Management indicated this capital position should fund operations into positive operating cash flow following the launch period. The company is also pursuing international expansion, having submitted a Marketing Authorization Application to European regulators in March 2026 and securing commercialization partnerships in the Middle East and other regions.
Analysts have maintained a largely positive outlook despite the disappointing quarter, with an average price target of $51.29, according to market data. Seven analysts cover the stock, with six rating it a 'buy' and one a 'strong buy.' The shares remain sharply below their 52-week high of $50.40 reached earlier in the launch cycle.
The company provided no formal financial guidance for 2026, leaving investors to assess the commercial trajectory based on management commentary about prescription trends and expansion plans. The sales force expansion and increased advertising spend in the current quarter suggest losses could remain elevated as LENZ attempts to accelerate adoption of VIZZ in a competitive ophthalmic market.
Presbyopia represents a significant commercial opportunity, but LENZ faces the challenge of establishing a new product category in an area where many patients have grown accustomed to reading glasses or contact lenses. The early prescription data shows some physician interest, but the revenue miss indicates that converting awareness into consistent prescriptions may take longer than investors had anticipated.